Throughout the COVID-19 pandemic, Saint Luke’s Health System is committed to providing exceptional care for all patients and a safe and healthy atmosphere for our team.

Empagliflozin helps lower diastolic pulmonary artery pressure in patients who have heart failure with either reduced ejection fraction or preserved ejection fraction, regardless of diabetes status, according to results of the EMBRACE HF trial. Pressures were monitored remotely in patients who had an existing implanted device.

“We saw an early, significant effect on lowering pulmonary artery diastolic pressure that became apparent within a few weeks and continued to widen over time,” said Mikhail Kosiborod, MD, Saint Luke’s Mid America Heart Institute, Kansas City, MO.

Pulmonary artery pressure is a strong predictor of clinical status, hospitalizations and death that had not previously been examined with sodium-glucose cotransporter 2 (SGLT2) inhibitors in this context, he added.

Read the full article on TCTMD: EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

Read more >

Related Content

Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital I am a Saint Luke's Nurse The room to grow, the tools to succeed Nurses are the lifeblood of Saint Luke’s compassionate...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse PractitionerSaint Luke’s East Hospital

Read more >
Person, Text, Female, Clothing, Apparel, Worker, Woman
Brenda's story

"We were able to sustain her long enough so she could make that closure with her family." Brenda Messer, Registered NurseSaint Luke’s Hospital of Kansas City

Read more >